T1	Participants 291 348	patients with breast cancer, prostate cancer and myeloma.
T2	Participants 600 783	in patients with bone metastases from tumors poorly responsive to chemotherapy, with the aims of evaluating the effects of this drug on symptoms control and bone metastases evolution.
T3	Participants 784 802	Sixty-six patients
T4	Participants 794 832	patients with poorly responsive tumors
T5	Participants 784 832	Sixty-six patients with poorly responsive tumors
